Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2013 Jun 11;5613:5351-81. doi: 10.1021/jm400177t.
Show Gene links
Show Anatomy links
Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.
Santangelo Freel RM, Ogden KK, Strong KL, Khatri A, Chepiga KM, Jensen HS, Traynelis SF, Liotta DC.
???displayArticle.abstract???
We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler-Napieralski conditions were employed in the key step for the conversion of acyclic amides to the corresponding tetrahydroisoquinoline-containing analogs. Compounds were evaluated using both two-electrode voltage clamp recordings from Xenopus laevis oocytes and imaging of mammalian BHK cells loaded with Ca(2+)-sensitive dyes. The most potent analogues had EC50 values of 300 nM and showed over 2-fold potentiation of the response to maximally effective concentrations of glutamate and glycine but had no effect on responses from NMDA receptors containing the GluN2A or GluN2B subunits AMPA, kainate, and GABA or glycine receptors or a variety of other potential targets. These compounds represent a potent class of small molecule subunit-selective potentiators of NMDA receptors.
???displayArticle.pubmedLink???
23627311 ???displayArticle.pmcLink???PMC4850841 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
aan het Rot,
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
2010, Pubmed
aan het Rot,
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
2010,
Pubmed Acker,
Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators.
2011,
Pubmed Akazawa,
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.
1994,
Pubmed Anson,
Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors.
1998,
Pubmed Antonov,
Binding sites for permeant ions in the channel of NMDA receptors and their effects on channel block.
1998,
Pubmed Banke,
Activation of NR1/NR2B NMDA receptors.
2003,
Pubmed Bettini,
Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
2010,
Pubmed Chen,
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.
2008,
Pubmed
,
Xenbase Citri,
Synaptic plasticity: multiple forms, functions, and mechanisms.
2008,
Pubmed Costa,
Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.
2012,
Pubmed
,
Xenbase Costa,
A novel family of negative and positive allosteric modulators of NMDA receptors.
2010,
Pubmed
,
Xenbase Coyle,
NMDA receptor and schizophrenia: a brief history.
2012,
Pubmed Cull-Candy,
Role of distinct NMDA receptor subtypes at central synapses.
2004,
Pubmed Dravid,
Activation of recombinant NR1/NR2C NMDA receptors.
2008,
Pubmed Dravid,
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.
2010,
Pubmed
,
Xenbase Durand,
Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C.
1993,
Pubmed
,
Xenbase Endele,
Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.
2010,
Pubmed Erreger,
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors.
2007,
Pubmed
,
Xenbase Faden,
The role of excitatory amino acids and NMDA receptors in traumatic brain injury.
1989,
Pubmed Furukawa,
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.
2003,
Pubmed Hallett,
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
2004,
Pubmed Hansen,
Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors.
2011,
Pubmed
,
Xenbase Hansen,
Subunit-selective allosteric inhibition of glycine binding to NMDA receptors.
2012,
Pubmed Hansen,
Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase Heresco-Levy,
N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade.
2000,
Pubmed Hillman,
Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory.
2011,
Pubmed Irvine,
Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors.
2012,
Pubmed Jones,
Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones.
2005,
Pubmed Karakas,
Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.
2011,
Pubmed
,
Xenbase Kashiwagi,
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore.
2002,
Pubmed
,
Xenbase Kerchner,
Silent synapses and the emergence of a postsynaptic mechanism for LTP.
2008,
Pubmed Korotkova,
NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory.
2010,
Pubmed Kuryatov,
Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins.
1994,
Pubmed
,
Xenbase Laube,
Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit.
1997,
Pubmed Lisman,
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
2008,
Pubmed Masuko,
Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors.
1999,
Pubmed
,
Xenbase Menniti,
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
2013,
Pubmed Milnerwood,
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease.
2010,
Pubmed Moghaddam,
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
2012,
Pubmed Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed Morikawa,
Attenuation of focal ischemic brain injury in mice deficient in the epsilon1 (NR2A) subunit of NMDA receptor.
1998,
Pubmed Morris,
PCP: from pharmacology to modelling schizophrenia.
2005,
Pubmed Mosley,
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase Mullasseril,
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.
2010,
Pubmed Nakazawa,
GABAergic interneuron origin of schizophrenia pathophysiology.
2012,
Pubmed Ogden,
New advances in NMDA receptor pharmacology.
2011,
Pubmed Ono,
18F-labeled flavones for in vivo imaging of beta-amyloid plaques in Alzheimer's brains.
2009,
Pubmed Park,
The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat.
1988,
Pubmed Preskorn,
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
2008,
Pubmed Rebola,
Activity-dependent synaptic plasticity of NMDA receptors.
2010,
Pubmed Reisberg,
Memantine in moderate-to-severe Alzheimer's disease.
2003,
Pubmed Sakurada,
Alteration of Ca2+ permeability and sensitivity to Mg2+ and channel blockers by a single amino acid substitution in the N-methyl-D-aspartate receptor.
1993,
Pubmed
,
Xenbase Santangelo Freel,
Correction to Synthesis and Structure Activity Relationship of Tetrahydroisoquinoline-Based Potentiators of GluN2C and GluN2D Containing N-Methyl-d-aspartate Receptors.
2014,
Pubmed Schwartz,
Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.
2012,
Pubmed Sheinin,
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine.
2001,
Pubmed
,
Xenbase Simon,
Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain.
1984,
Pubmed Suetake-Koga,
In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist.
2006,
Pubmed Tolias,
The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines.
2005,
Pubmed Traynelis,
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.
1998,
Pubmed
,
Xenbase Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed Traynelis,
Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines.
1995,
Pubmed
,
Xenbase Vicini,
Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors.
1998,
Pubmed Williams,
Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor.
1990,
Pubmed Wu,
Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.
2009,
Pubmed Wu,
Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor.
1991,
Pubmed Wyllie,
Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors.
1998,
Pubmed
,
Xenbase Youte,
An enantioselective access to 1-alkyl-1,2,3,4-tetrahydroisoquinolines. Application to a new synthesis of (-)-argemonine.
2004,
Pubmed
